Stereotaxis, Inc.
AMEX:STXSMedical - Instruments & Supplies
+$0.05 today
- Market cap
- $94.80M
- Beta
- 1.32
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.22
Volume 0.90M
Average 0.39M
STXS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Stereotaxis, Inc.AMEX: STXS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development growth accelerates
Q1 FY2026 research & development of $2.4M rose 2.0% year over year, ahead of the -4.4% change in trailing-twelve-month research & development. Sequentially, it fell 11.5% from the prior quarter. Over 3 fiscal years it compounded at -3.9% a year.
Context
- Research & development amounted to 29.0% of revenue in FY2025, down 7.3 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +2.0% holds above the trailing-twelve-month pace of -4.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 9.38M USD
- Year-over-year change
- -3.9%
- 4-year CAGR
- -2.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.38M | -3.9% |
| FY2024 | 2024-12-31 | 9.76M | -5.0% |
| FY2023 | 2023-12-31 | 10.27M | -2.7% |
| FY2022 | 2022-12-31 | 10.56M | +3.5% |
| FY2021 | 2021-12-31 | 10.2M | — |
Research & Development vs competitors
How STXS compares with its peers on the latest reported figures
- STXS's LTM Mar 2026 research & development of $9.43M is the 3rd highest of the 5 companies compared; the peer median is $10.57M.
- Its year-over-year change of -4.4% is the 4th highest of 5, against a peer median of +11.8%.
- Research & development amounts to 30.2% of revenue for STXS, versus a peer median of 32.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.64M | +9.2% | +8.3% | 27.8% | |
| LTM Mar 2026 | $15.04M | +14.4% | +8.5% | 37.0% | |
| LTM Mar 2026 | $9.43M | -4.4% | -3.9% | 30.2% | |
| LTM Mar 2026 | $6.11M | -11.4% | -6.7% | 5814.3% | |
| LTM Mar 2026 | $3.67M | +63.3% | +253.7% | 7.6% | |
| Peer median (excluding STXS) | $10.57M | +11.8% | +8.4% | 32.4% | |
Competitors are the stored peer set for STXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 35.02M | 28.15M | 26.77M | 26.92M | 32.38M |
| Cost of Revenue | 11.79M | 9.68M | 11.91M | 12.32M | 15.31M |
| Gross Profit | 23.23M | 18.47M | 14.86M | 14.59M | 17.07M |
| Gross Margin | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% |
| Research & Development | 10.2M | 10.56M | 10.27M | 9.76M | 9.38M |
| Selling, General & Admin | 25.92M | 26.69M | 26.43M | 29.57M | 30.29M |
| Operating Expenses | 36.12M | 37.25M | 36.7M | 39.33M | 39.18M |
| Depreciation & Amortization | 106K | 429K | 595K | 969K | 1.56M |
| EBITDA | (10.6M) | (17.86M) | (20.12M) | (23.08M) | (20.09M) |
| EBITDA Margin | -30.3% | -63.5% | -75.1% | -85.7% | -62.0% |
| Operating Income | (12.89M) | (18.78M) | (21.84M) | (24.74M) | (22.11M) |
| Operating Margin | -36.8% | -66.7% | -81.6% | -91.9% | -68.3% |
| Interest Income | 0 | 484K | 1.1M | 694K | 467K |
| Interest Expense | 10.07K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.17M | 484K | 1.13M | 694K | 469K |
| Income Before Tax | (10.72M) | (18.29M) | (20.71M) | (24.05M) | (21.64M) |
| Pre-Tax Margin | -30.6% | -65.0% | -77.4% | -89.3% | -66.8% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.72M) | (18.29M) | (20.71M) | (24.05M) | (21.64M) |
| Net Margin | -30.6% | -65.0% | -77.4% | -89.3% | -66.8% |
| EPS (Basic) | (0.16) | (0.26) | (0.27) | (0.30) | (0.25) |
| EPS (Diluted) | (0.16) | (0.26) | (0.27) | (0.30) | (0.25) |
| Weighted Avg Shares | 75.56M | 76.06M | 80.7M | 85.18M | 90.96M |
| Weighted Avg Shares (Diluted) | 75.56M | 76.06M | 80.7M | 85.18M | 90.96M |
Stereotaxis, Inc.
AMEX:STXS
Intrinsic Alpha fair value
Locked
Current Price
$0.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.